247 related articles for article (PubMed ID: 32905294)
1. Real-world treatment patterns and survival in stage IV non-small-cell lung cancer in Canada.
Seung SJ; Hurry M; Walton RN; Evans WK
Curr Oncol; 2020 Aug; 27(4):e361-e367. PubMed ID: 32905294
[TBL] [Abstract][Full Text] [Related]
2. Trends in treatment patterns and survival outcomes in advanced non-small cell lung cancer: a Canadian population-based real-world analysis.
Carroll R; Bortolini M; Calleja A; Munro R; Kong S; Daumont MJ; Penrod JR; Lakhdari K; Lacoin L; Cheung WY
BMC Cancer; 2022 Mar; 22(1):255. PubMed ID: 35264135
[TBL] [Abstract][Full Text] [Related]
3. A Population-based Study of Treatment Patterns and Survival of Patients With De Novo Stage IV Non-Small Cell Lung Cancer.
Batra A; Yusuf D; Hurry M; Walton RN; Devost N; Farrer C; Cheung WY
Am J Clin Oncol; 2021 Oct; 44(10):512-518. PubMed ID: 34380947
[TBL] [Abstract][Full Text] [Related]
4. Comparison of patient outcomes according to histology among pemetrexed-treated patients with stage IIIB/IV non-small-cell lung cancer in two phase II trials.
Zinner RG; Novello S; Peng G; Herbst R; Obasaju C; Scagliotti G
Clin Lung Cancer; 2010 Mar; 11(2):126-31. PubMed ID: 20199979
[TBL] [Abstract][Full Text] [Related]
5. Real-world first-line treatment and overall survival in non-small cell lung cancer without known EGFR mutations or ALK rearrangements in US community oncology setting.
Abernethy AP; Arunachalam A; Burke T; McKay C; Cao X; Sorg R; Carbone DP
PLoS One; 2017; 12(6):e0178420. PubMed ID: 28644837
[TBL] [Abstract][Full Text] [Related]
6. Bayesian network meta-comparison of maintenance treatments for stage IIIb/IV non-small-cell lung cancer (NSCLC) patients with good performance status not progressing after first-line induction chemotherapy: results by performance status, EGFR mutation, histology and response to previous induction.
Tan PS; Lopes G; Acharyya S; Bilger M; Haaland B
Eur J Cancer; 2015 Nov; 51(16):2330-44. PubMed ID: 26364517
[TBL] [Abstract][Full Text] [Related]
7. Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With First-line Therapies for Medicare Patients 65 Years and Older With Advanced Non-small-cell Lung Cancer: A Retrospective Study.
Bittoni MA; Arunachalam A; Li H; Camacho R; He J; Zhong Y; Lubiniecki GM; Carbone DP
Clin Lung Cancer; 2018 Sep; 19(5):e629-e645. PubMed ID: 29885945
[TBL] [Abstract][Full Text] [Related]
8. A multicenter survey of first-line treatment patterns and gene aberration test status of patients with unresectable Stage IIIB/IV nonsquamous non-small cell lung cancer in China (CTONG 1506).
Zhou Q; Song Y; Zhang X; Chen GY; Zhong DS; Yu Z; Yu P; Zhang YP; Chen JH; Hu Y; Feng GS; Song X; Shi Q; Yang LL; Zhang PH; Wu YL
BMC Cancer; 2017 Jul; 17(1):462. PubMed ID: 28673332
[TBL] [Abstract][Full Text] [Related]
9. Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative.
Soares M; Antunes L; Redondo P; Borges M; Hermans R; Patel D; Grimson F; Munro R; Chaib C; Lacoin L; Daumont M; Penrod JR; O'Donnell JC; Bento MJ; Rocha Gonçalves F
BMC Pulm Med; 2020 Sep; 20(1):240. PubMed ID: 32912174
[TBL] [Abstract][Full Text] [Related]
10. EGFR mutation prevalence, real-world treatment patterns, and outcomes among patients with resected, early-stage, non-small cell lung cancer in Canada.
Sara Kuruvilla M; Liu G; Syed I; Gwadry-Sridhar F; Sheffield BS; Sachdeva R; Pencz A; Zhan L; Hueniken K; Patel D; Balaratnam K; Khan K; Grant B; Noy S; Singh K; Liu L; Rakibuz-Zaman M; Moldaver D; Kate Shanahan M; Cheema PK
Lung Cancer; 2022 Nov; 173():58-66. PubMed ID: 36152478
[TBL] [Abstract][Full Text] [Related]
11. Real-world chemotherapy treatment patterns in metastatic non-small cell lung cancer: Are patients undertreated?
Sacher AG; Le LW; Lau A; Earle CC; Leighl NB
Cancer; 2015 Aug; 121(15):2562-9. PubMed ID: 25891153
[TBL] [Abstract][Full Text] [Related]
12. Comparative effectiveness of three platinum-doublet chemotherapy regimens in elderly patients with advanced non-small cell lung cancer.
Zhu J; Sharma DB; Chen AB; Johnson BE; Weeks JC; Schrag D
Cancer; 2013 Jun; 119(11):2048-60. PubMed ID: 23564469
[TBL] [Abstract][Full Text] [Related]
13. Retrospective cohort study of unresectable stage III non-small-cell lung cancer in Canada.
Seung SJ; Hurry M; Walton RN; Evans WK
Curr Oncol; 2020 Aug; 27(4):e354-e360. PubMed ID: 32905267
[TBL] [Abstract][Full Text] [Related]
14. Real-world treatment patterns and costs in a US Medicare population with metastatic squamous non-small cell lung cancer.
Davis KL; Goyal RK; Able SL; Brown J; Li L; Kaye JA
Lung Cancer; 2015 Feb; 87(2):176-85. PubMed ID: 25532680
[TBL] [Abstract][Full Text] [Related]
15. Age and treatment of non-small-cell lung cancer: a database analysis in elderly patients.
Berghmans T; Tragas G; Sculier JP
Support Care Cancer; 2002 Nov; 10(8):619-23. PubMed ID: 12436220
[TBL] [Abstract][Full Text] [Related]
16. Concurrent EGFR-TKI and Thoracic Radiotherapy as First-Line Treatment for Stage IV Non-Small Cell Lung Cancer Harboring EGFR Active Mutations.
Zheng L; Wang Y; Xu Z; Yang Q; Zhu G; Liao XY; Chen X; Zhu B; Duan Y; Sun J
Oncologist; 2019 Aug; 24(8):1031-e612. PubMed ID: 31040256
[TBL] [Abstract][Full Text] [Related]
17. Efficacy differences of pemetrexed by histology in pretreated patients with stage IIIB/IV non-small cell lung cancer: review of results from an open-label randomized phase II study.
Kubota K; Niho S; Enatsu S; Nambu Y; Nishiwaki Y; Saijo N; Fukuoka M
J Thorac Oncol; 2009 Dec; 4(12):1530-6. PubMed ID: 19755925
[TBL] [Abstract][Full Text] [Related]
18. A retrospective analysis of outcomes across histological subgroups in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin for advanced non-small cell lung cancer.
Treat J; Edelman MJ; Belani CP; Socinski MA; Monberg MJ; Chen R; Obasaju CK;
Lung Cancer; 2010 Dec; 70(3):340-6. PubMed ID: 20347506
[TBL] [Abstract][Full Text] [Related]
19. Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With Second-Line Therapies for Medicare Patients With Advanced Non-Small-Cell Lung Cancer.
Arunachalam A; Li H; Bittoni MA; Camacho R; Cao X; Zhong Y; Lubiniecki GM; Carbone DP
Clin Lung Cancer; 2018 Sep; 19(5):e783-e799. PubMed ID: 29983370
[TBL] [Abstract][Full Text] [Related]
20. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
